| P50 | author | Isabel Lastres-Becker | Q73043002 |
| P2093 | author name string | Fernando Berrendero | |
| | Javier Fernández-Ruiz | |
| | Jorge Manzanares | |
| | Henrik H Hansen | |
| | José A Ramos | |
| | Alberto Pérez-Rosado | |
| | Rosario De Miguel | |
| P2860 | cites work | The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1) | Q28343961 |
| | Cannabinoids inhibit excitatory neurotransmission in the substantia nigra pars reticulata | Q28377147 |
| | Anandamide, an endogenous ligand of the cannabinoid receptor, induces hypomotility and hypothermia in vivo in rodents. | Q52060269 |
| | Time-course of the effects of anandamide, the putative endogenous cannabinoid receptor ligand, on extrapyramidal function. | Q54001516 |
| | The anandamide transport inhibitor AM404 activates vanilloid receptors. | Q31384563 |
| | Cannabinoid receptor ligands: clinical and neuropharmacological considerations, relevant to future drug discovery and development | Q31522100 |
| | Differential loss of striatal projection neurons in Huntington disease | Q33637273 |
| | Fetal tissue transplants in animal models of Huntington's disease: the effects on damaged neuronal circuitry and behavioral deficits | Q33869424 |
| | Functional role of high-affinity anandamide transport, as revealed by selective inhibition | Q34436019 |
| | Brain cannabinoid systems as targets for the therapy of neurological disorders | Q34492167 |
| | Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. | Q34602111 |
| | Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system | Q34745063 |
| | Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human | Q35120095 |
| | Mesencephalic dopamine neurons regulate the expression of neuropeptide mRNAs in the rat forebrain | Q37413174 |
| | Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry | Q38331458 |
| | Aging, energy, and oxidative stress in neurodegenerative diseases. | Q40478731 |
| | The activation of cannabinoid receptors in striatonigral GABAergic neurons inhibited GABA uptake. | Q42450193 |
| | Adjuncts to dopamine replacement: a pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease | Q42464432 |
| | Unilateral 6-hydroxydopamine lesions of nigrostriatal dopaminergic neurons increased CB1 receptor mRNA levels in the caudate-putamen | Q42487505 |
| | Cannabinoid receptor messenger RNA levels decrease in a subset of neurons of the lateral striatum, cortex and hippocampus of transgenic Huntington's disease mice | Q42490465 |
| | The cannabinoid receptor agonist WIN 55,212-2 reduces D2, but not D1, dopamine receptor-mediated alleviation of akinesia in the reserpine-treated rat model of Parkinson's disease | Q42546097 |
| | Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease | Q43504648 |
| | Changes in endocannabinoid transmission in the basal ganglia in a rat model of Huntington's disease | Q43669613 |
| | Effects of systemic 3-nitropropionic acid-induced lesions of the dorsal striatum on cannabinoid and mu-opioid receptor binding in the basal ganglia. | Q44330257 |
| | Selective vulnerability in Huntington's disease: preferential loss of cannabinoid receptors in lateral globus pallidus. | Q45289172 |
| | Loss of cannabinoid receptors in the substantia nigra in Huntington's disease. | Q45290294 |
| | Quantifiable bradykinesia, gait abnormalities and Huntington's disease-like striatal lesions in rats chronically treated with 3-nitropropionic acid | Q45294402 |
| | Hyperactivity and hypoactivity in a rat model of Huntington's disease: the systemic 3-nitropropionic acid model | Q45295346 |
| | Differential responses of extracellular GABA to intrastriatal perfusions of 3-nitropropionic acid and quinolinic acid in the rat. | Q45295617 |
| | Advances in Huntington's disease: implications for experimental therapeutics | Q45296397 |
| | Comparison of intrastriatal injections of quinolinic acid and 3-nitropropionic acid for use in animal models of Huntington's disease | Q45296895 |
| | Brain neurotransmitter deficits in mice transgenic for the Huntington's disease mutation | Q45297581 |
| | The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease | Q45300428 |
| | Major strain differences in response to chronic systemic administration of the mitochondrial toxin 3-nitropropionic acid in rats: implications for neuroprotection studies | Q45300432 |
| | Huntington chorea is not associated with hyperactivity of nigrostriatal dopaminergic neurons: Studies in postmortem tissues and in rats with kainic acid lesions | Q45304178 |
| | Systemic 3-nitropropionic acid: behavioral deficits and striatal damage in adult rats | Q45307246 |
| | Elevated circulating levels of anandamide after administration of the transport inhibitor, AM404. | Q46163967 |
| | Ipsilateral turning behavior induced by unilateral microinjections of a cannabinoid into the rat subthalamic nucleus | Q47963301 |
| | Extrapyramidal and neuroendocrine effects of AM404, an inhibitor of the carrier-mediated transport of anandamide | Q48136699 |
| | Neuron-specific enolase (NSE) and non-neuronal enolase (NNE) mRNAs are co-expressed in neurons of the rat cerebellum: in situ hybridization histochemistry | Q48255621 |
| | Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent | Q48332786 |
| | Age-dependent vulnerability of the striatum to the mitochondrial toxin 3-nitropropionic acid. | Q48365871 |
| | Tissue-specific generation of two preprotachykinin mRNAs from one gene by alternative RNA splicing | Q48384593 |
| | 3-Nitropropionic acid's lethal triplet: cooperative pathways of neurodegeneration. | Q48403701 |
| | Cannabinoid effects in basal ganglia in a rat model of Parkinson's disease | Q48435185 |
| | Presynaptic inhibition of GABAergic inputs to rat substantia nigra pars reticulata neurones by a cannabinoid agonist | Q48484213 |
| | Effects of repeated administration of estradiol benzoate on tubero-infundibular GABAergic activity in male rats | Q48500490 |
| | Activation of the cannabinoid receptor by delta 9-tetrahydrocannabinol reduces gamma-aminobutyric acid uptake in the globus pallidus. | Q48962147 |
| | Modulation of GABAergic transmission in the globus pallidus by the synthetic cannabinoid WIN 55,212-2. | Q49018761 |
| P433 | issue | 1 | |
| P921 | main subject | Huntington's disease | Q190564 |
| | endocannabinoids | Q10483908 |
| P304 | page(s) | 23-35 | |
| P577 | publication date | 2002-04-01 | |
| P1433 | published in | Synapse | Q7662025 |
| P1476 | title | Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease | |
| P478 | volume | 44 | |